



Announcement Summary

Entity name

BOTANIX PHARMACEUTICALS LTD

Announcement Type

New announcement

Date of this announcement

17/2/2026

The Proposed issue is:

An offer of securities under a securities purchase plan
A placement or other type of issue

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
BOT	ORDINARY FULLY PAID	83,333,334

+Record date

16/2/2026

Offer closing date

7/4/2026

+Issue date

14/4/2026

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
BOT	ORDINARY FULLY PAID	666,666,667

Proposed +issue date

8/4/2026

Refer to next page for full details of the announcement

For personal use only



Part 1 - Entity and announcement details

1.1 Name of +Entity

BOTANIX PHARMACEUTICALS LTD

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

009109755

1.3 ASX issuer code

BOT

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/2/2026

1.6 The Proposed issue is:

An offer of +securities under a +securities purchase plan

A placement or other type of issue

For personal use only



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis?

Yes

4A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	31/3/2026	Estimated	No

Comments

Shareholder approval is being sought for all shares to be issued under the SPP.

For personal use only



Part 4B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

BOT : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

BOT : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

83,333,334

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)?

No

Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)?

No

Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)?

No

Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)?

Yes

Is the maximum acceptance unit based or dollar based?

Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

Describe all the applicable parcels available for this offer in number of securities or dollar value

\$2,000, \$5,000, \$7,500, \$10,000, \$15,000, \$20,000, \$30,000

Offer price details

Has the offer price been determined?

Yes

In what currency will the offer What is the offer price per

For personal use only



be made?	+security?
AUD - Australian Dollar	AUD 0.06000

Oversubscription & Scale back details

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

The Company intends to raise \$5 million before costs through the SPP. The Company will accept oversubscriptions.
The scale pack policy will be detailed in the Prospectus which contains the SPP offer.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

For personal use only

Part 4C - Timetable

4C.1 Date of announcement of +security purchase plan

17/2/2026

4C.2 +Record date

16/2/2026

4C.3 Date on which offer documents will be made available to investors

2/3/2026

4C.4 Offer open date

2/3/2026

4C.5 Offer closing date

7/4/2026

4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer

14/4/2026

Part 4D - Listing Rule requirements

4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements?

No

4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

No

4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?



No

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?

Yes

4E.1a Who is the lead manager/broker?

Euroz Hartleys Limited ACN and Canaccord Genuity (Australia) Limited will act as joint lead managers and underwriters of the SPP

4E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

1.50% of the of the issue size (excluding oversubscriptions)

4E.2 Is the proposed offer to be underwritten?

Yes

4E.2a Who are the underwriter(s)?

Euroz Hartleys Limited ACN and Canaccord Genuity (Australia) Limited will act as joint lead managers and underwriters of the SPP

4E.2b What is the extent of the underwriting (ie the amount or proportion of the issue that is underwritten)?

The SPP is underwritten to a total of \$5million.

4E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)?

1.5% of the total funds underwritten and an issue of 1 for 3 options exercisable at \$0.06 on or before 31 January 2027.

4E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated.

Please see Annexure B of the ASX announcement titled "Botanix Receives Capital Raise Commitments of ~A\$45 million to fund further API purchases" released today for a summary of the terms of the Underwriting Agreement.

4E.2e Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed offer?

No

4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

For personal use only

Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

The proceeds will be applied towards API and manufacturing component purchases, alternate API supplier setup, operating expenses and working capital, as well as transaction costs of the Raising.

4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?

No

4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer

SPP will be available to the Company's shareholders in Australia or New Zealand. Shareholders resident in China, France, Germany, Hong Kong, Papua New Guinea, Portugal, Singapore, South Africa, Thailand, UAE, UK and USA will not be eligible to participate.

4F.3 URL on the entity's website where investors can download information about the proposed offer

<https://www.asx.com.au/markets/company/BOT>



4F.4 Any other information the entity wishes to provide about the proposed offer

For personal use only



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	31/3/2026	Estimated	No

Comments

Tranche two of the Placement (418,672,194 shares) will be subject to shareholder approval. Director participation in the Placement will also be subject to shareholder approval.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

Details of +securities proposed to be issued

ASX +security code and description

BOT : ORDINARY FULLY PAID

Number of +securities proposed to be issued

666,666,667

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.06000

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?



Yes

Part 7C - Timetable

7C.1 Proposed +issue date

8/4/2026

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

Yes

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

31/3/2026

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Euroz Hartleys Limited and Canaccord Genuity (Australia) Limited acted as Joint Lead Managers to the Placement

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

A cash fee equal to 5% of the proceeds raised under the Placement and a discretionary fee of 1% of the proceeds raised under the Placement.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

The proceeds will be applied towards API and manufacturing component purchases, alternate API supplier setup, operating expenses and working capital, as well as transaction costs of the Raising.

For personal use only



7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

For further information on the Placement and SPP, please refer to the announcement titled "Botanix received capital raise commitments of ~A\$45 million to fund further API purchases" released on 17 February 2026 at <https://www.asx.com.au/markets/company/BOT>

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

For personal use only